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Abstract: N-Glycans direct protein function, stability, folding
and targeting, and influence immunogenicity. While most
glycosidases that process N-glycans cleave a single sugar
residue at a time, enzymes from glycoside hydrolase family
99 are endo-acting enzymes that cleave within complex N-
glycans. Eukaryotic Golgi endo-1,2-a-mannosidase cleaves
glucose-substituted mannose within immature glucosylated
high-mannose N-glycans in the secretory pathway. Certain
bacteria within the human gut microbiota produce endo-1,2-
a-mannanase, which cleaves related structures within fungal
mannan, as part of nutrient acquisition. An unconventional
mechanism of catalysis was proposed for enzymes of this
family, hinted at by crystal structures of imino/azasugars
complexed within the active site. Based on this mechanism,
we developed the synthesis of two glycosides bearing a
spiro-epoxide at C-2 as electrophilic trap, to covalently bind
a mechanistically important, conserved GH99 catalytic resi-
due. The spiro-epoxyglycosides are equipped with a fluores-
cent tag, and following incubation with recombinant
enzyme, allow concentration, time and pH dependent visual-
ization of the bound enzyme using gel electrophoresis.
Introduction
N-Linked glycans are complex oligosaccharides linked to aspar-
agine (Asn) residues in eukaryotic proteins.[1] They play impor-
tant roles in protein function, stability, folding and targeting
and are essential for a range of cellular functions.[2] Erroneous
N-glycan composition is associated with various diseases in-
cluding viral infections, Alzheimer’s disease and metastatic
cancer.[3–5] Assembly of the N-glycan commences in the endo-
plasmic reticulum (ER) where the 14-mer polysaccharide
Glc3Man9GlcNAc2-diphosphodolichol is coupled to the Asn resi-
due of the target protein by the enzyme oligosaccharyl trans-
ferase. The glycan undergoes stepwise “trimming” of the non-
reducing end glucoside residues by a-glucosidase I and II, after
which a-mannosidase I truncates the resulting oligomanno-
side.[6] The resulting Man5GlcNAc2 structure is redecorated to
yield complex N-glycans. Because a-glucosidases I and II play
important roles in the early stages of glycan maturation, these
enzymes were investigated as therapeutic targets to control
diseases involving incorrect N-glycosylation.[7–10] However, in-
hibition of these enzymes did not block N-glycosylation:
mouse lymphoma cells inhibited with the a-glucosidase inhibi-
tor castanospermine as well as mutant cell lines lacking a-glu-
cosidase II retained up to 80% of normal N-glycan matura-
tion.[11–13] Spiro and co-workers identified endo-1,2-a-mannosi-
dase,[14, 15] (later classified as a member of glucoside hydrolase
family 99 (GH99); see http://cazypedia.org),[16] residing in the
Golgi apparatus, which circumvents inhibition of ER a-glucosi-
dase I and II. The enzyme cleaves glucose-substituted mannose
from the A-branch of ER escaped immature N-glycoproteins
bearing Glc1–3Man9GlcNAc2, releasing Glc1-3Man. The resulting
Man8GlcNAc2 glycoprotein subsequently re-enters the normal
processing route in the Golgi apparatus.
Bacterial GH99 orthologs including Bacteroides thetaiotaomi-
cron (Bt) and Bacteroides xylanisolvens (Bx) enzymes possess
endo-1,2-a-mannosidase activity, but are more appropriately
described as endo-1,2-a-mannanases, as they act on yeast
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mannan[17] and exhibit a tenfold preference for mannan-based
substrates versus the equivalent glucose-substituted man-
nans.[18] Several imino/azasugar inhibitors for GH99 endoman-
nosidase have been developed, including a-glucopyranosyl-
1,3-isofagomine (GlcIFG, 1, Figure 1) and a-mannopyranosyl-
1,3-isofagomine (ManIFG, 2). Due to a preference for a manno-
pyranosyl residue in subsite @2 GH99 endo-1,2-a-mannanases
show a greater affinity for 2 than for 1.[18] Recently, mannoeur-
omycin (ManNOE, 3), which features a 2-hydroxyl allowing in-
teraction with the proposed general base/acid residue, has
been reported as the most potent endo-1,2-a-mannanase in-
hibitor for bacterial GH99 enzymes with KD values in the low
nanomolar range.[19] Additionally, fluorescent[20] and fluorogen-
ic[18,21] substrates have been developed for monitoring endo-
1,2-a-mannosidase/mannanase activity.
Family GH99 endo-1,2-a-mannosidases/mannanases cleave
their substrate glycosides with retention of anomeric stereo-
chemistry; however, instead of the classical Koshland double-
displacement mechanism for retaining enzymes,[22] an unusual
neighboring group participation hydrolytic mechanism was
proposed in which a glutamate residue (Glu333 in BxGH99) acts
as a general base assisting OH-2 to displace the aglycon via a
1,2-anhydro sugar that is subsequently hydrolyzed by water
(Figure 1B).[23] In order to study enzyme function in biological
settings, screen for inhibitors, as well as to further illuminate
the catalytic reaction mechanism, the development of a mech-
anism-based irreversible inhibitor would be of interest. Here,
the synthesis is described of two putative covalent inhibitors 4
and 5, designed to, respectively inhibit eukaryotic GH99 endo-
1,2-a-mannosidases and bacterial endo-1,2-a-mannanases and
which vary in the nature of the pyranoside at the non-reducing
end (Figure 1A, right). Both compounds contain a spiro-epox-
ide at position C-2 to serve as an electrophile to trap the gen-
eral base residue. Inspection of the crystal structures of
BxGH99 suggests that the general base will be situated close
to the methylene group of the spiro-epoxide, where it may
open the ring via nucleophilic attack resulting in a covalent in-
termediate (Figure 1C).[23] The compounds are also equipped
with a reporter tag, allowing active enzyme labeling by activi-
ty-based protein profiling (ABPP)[24] protocols, the efficiency of
which is reported as well.
Results
Acceptor 7 was synthesized by 4,6-silylidene protection of
compound 6,[25] followed by formation of the 2,3-orthoben-
zoate and final treatment with acid (Scheme 1).[26] Glucopyra-
noside donor 9 was synthesized from thiophenyl b-glucopyra-
noside 8.[27] While 4,6-silylidene protection proceeded smooth-
ly, elevated temperatures were required to install the TBS-
Figure 1. (A) Known GH99 endo-1,2-a-mannosidase inhibitors (1–3) and fluorescent spiro-epoxyglycosides 4 and 5 subject of this study. KD values are for B.
thetaiotaomicron endo-1,2-a-mannosidase (BtGH99). (B) The proposed catalytic mechanism for GH99 enzyme (amino acid numbering for B. xylanisolvens endo-
1,2-a-mannosidase (BxGH99)). (C) Anticipated covalent inhibition mechanism of GH99 enzymes.
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groups onto both secondary hydroxyl groups, presumably due
to steric hindrance. Using a similar approach, thiophenyl a-
mannopyranoside 10[28] was converted to protected thioman-
noside donor 11.
Glycosylation of acceptor 7 by 9 or 11 was achieved in an N-
iodosuccinimide (NIS)/trimethylsilyl triflate (TMSOTf) mediated
coupling at low temperature, affording 12g or 12m, respec-
tively. Both glycosylations proceeded in excellent yield and ste-
reoselectivity. Pedersen, Bols and co-workers[29] recently report-
ed that silylidene-protected mannosyl donors can be used for
stereoselective b-mannosylation. The contrasting selectivity ob-
tained here is likely the result of the steric buttressing effect of
the large silyl ether protecting groups at the C-2- and C-3-hy-
droxyls of 7, consistent with the steric effects that large pro-
tecting groups and functionalities have in glycosylations of
otherwise b-selective benzylidene-protected mannosyl
donors.[30] Thus, the b-face of mannosyl donor 11 is shielded
from attack by the incoming nucleophile. The glycosylation
stereoselectivity of glucosyl donor 9 can be rationalized by its
high reactivity. The “arming” silyl protecting groups allow this
donor to readily form an oxocarbenium ion, which will likely
take up a 4H3-like conformation, which is preferentially at-
tacked from the a-face to provide the 1,2-cis-linked prod-
uct.[31,32] Next, the benzoyl groups were deprotected under
Zempl8n conditions affording compounds 13g and 13m. The
alcohols were then oxidized with Dess–Martin periodinane
(DMP) to ketones 14g and 14m, which appeared to be in
equilibrium with the corresponding hydrates.
Transformation of ketones 14 into their corresponding spiro-
epoxides was explored next (Table 1). Reaction of 14g with di-
azomethane as methylenating agent[33] resulted in the forma-
tion of the equatorial (15g) and axial (16g) methylenes in a
1:1 ratio and in good yields (entry 1). Their absolute configura-
tion was determined by 1D-NOE difference experiments (see
Supplementary Information). Reaction of 14m with diazome-
thane also resulted in a mixture of 15m and 16m, in a 3:1
ratio, in favor of the equatorial methylene group in almost
quantitative yield (entry 2). We anticipated that a Corey–Chay-
kovsky epoxidation[34] using stabilized dimethylsulfoxonium
methylide would favor the formation of the equatorial methyl-
enes 15g and 15m. Indeed, also in these cases both isomers
were obtained, however the formation of axial methylenes was
still favored in both cases (entries 3 and 4). Finally, using the
more reactive dimethylsulfonium methylide, only the kinetical-
ly favored axial methylenes 16g and 16m were formed, albeit
in moderate yields (entries 5 and 6). With spiro-epoxides 16g
and 16m in hand, global deprotection was accomplished by
reaction with tetrabutylammonium fluoride (TBAF). Finally, a
fluorescent Cy5 tag was installed at the azide handle using
copper(I) catalyzed click chemistry, which after HPLC purifica-
tion afforded spiro-epoxyglycosides 4 and 5.
The ability of 4 and 5 to label recombinant Bt- and BxGH99
endo-1,2-a-mannanase was evaluated (Figure 2A). The com-
pounds label both enzymes in a concentration-dependent
manner, at concentrations as low as 100 nm. Previous studies
indicated a preference for a mannosyl residue at the @2 sub-
site of both enzymes.[18] However, no difference in potency of
labeling was observed. Studies on the effect of the pH de-
pendence on labeling revealed that both spiro-epoxyglyco-
sides label the enzymes maximally at pH 6–8, corresponding to
Scheme 1. Synthesis of fluorescent spiro-epoxyglycosides 4 and 5. Reagents and conditions: a) tBu2Si(OTf)2, 2,6-lutidine, DMF, @50 8C; b) PhC(OMe)3, CSA, 2 h,
then AcOH, H2O, 16 h, 57% over 2 steps; c) TBSOTf, DMAP, pyridine, 60 8C, 16 h, yield 9 : 85% over 2 steps; yield 11: 81% over 2 steps; d) donor 9 or 11, NIS,
TMSOTf, DCM, 4 a MS, @40 8C, 1 h, yield 12g : 92%; yield 12m : 88%; e) NaOMe, MeOH, DCM, yield 13g : 95%; yield 13m : 86%; f) DMP, DCM, yield 14g : 98%;
yield 14m : 96%; g) TBAF, THF, 5 days, yield 17: 97%; yield 18 : 74%; h) Cy5-alkyne,[47] CuSO4·5H2O, sodium ascorbate, DMF, rt, 16 h, yield 4 : 32%; yield 5 : 34%.
Table 1. Transformation of ketones 14g and 14m into their correspond-
ing spiro-epoxides.
Entry s.m. Conditions 15 :16 Yield [%][a]
1 14g
CH2N2, EtOH, 0 8C
1:1 78
2 14m 3:1 97
3 14g
SOMe3I, nBuLi, THF, 60 8C
1:5 83
4 14m 1:2 85
5 14g
SMe3I, NaH, DMSO, THF, @10 8C 0:1 506 14m 0:1 53
[a] Combined yield after column chromatography. s.m.= starting material.
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the pH optimum of GH99 enzymatic activity (Figure 2B).[23] No-
tably, more than one band is evident, suggesting enzyme deg-
radation under reducing SDS-PAGE conditions or alternatively
that multiple labelling events may be occurring. Next, labeling
of wild-type (WT) BxGH99 was compared to analo-
gous active-site mutants (Figure 2C). While WT
enzyme is labeled by spiro-epoxyglycosides 4 and 5
within 5 minutes, the general base mutant E333Q
and the catalytic acid mutant E336Q were not la-
beled in the same time period with these com-
pounds, suggesting that labeling is indeed activity-
based, and is consistent with reaction occurring in a
mechanism-based manner. However, incubation for
longer times resulted in labeling of the mutant en-
zymes, indicating that either the spiro-epoxide is sus-
ceptible to ring opening by the mutant catalytic resi-
dues, or that other residues may also be involved in
covalent labelling. Denaturation of BtGH99 and
BxGH99 completely abrogated labeling by spiro-ep-
oxyglycosides 4 and 5, indicating that labeling re-
quires the natively folded enzyme (Figure 2D).
To further evaluate whether covalent inhibition of
BtGH99 and BxGH99 is activity-based, the processing
of human a-galactosidase A (GLA) by these enzymes
was investigated (Figure 3A). GLA contains three N-
glycosylation sites, of which two are decorated with
oligo-mannose structures, and one contains complex
oligosaccharides low in mannose content.[35,36] We
have previously demonstrated that fluorescent a-gal-
acto-cyclophellitol aziridines such as TB340 covalent-
ly label GLA in activity-based manner.[37] Here, GLA
was pre-labeled with TB340 to enable fluorescent de-
tection on gel. Without additives, GLA gives a dis-
tinct major band at &50 kDa (Figure 3B, lane 1). In-
cubation of GLA with BtGH99 results in demannosyl-
ation of the two high-mannose N-glycans of GLA, re-
sulting in a shift of the GLA band into lower bands
at &42 kDa (lane 2). This shift in molecular weight is
similar to the shift observed when GLA is incubated with
Endo-H (lane 4), which causes demannosylation of high-man-
nose N-glycans by cleaving within the chitobiosyl core leaving
a residual GlcNAc on Asn. Treatment of GLA with PNGase-F
Figure 2. Fluorescent labeling of GH99 endomannanases. (A) Detection limit of Bt and Bx GH99 endomannanases (left and right, respectively), labeled with
various concentrations of fluorescent spiro-epoxyglycosides 4 or 5. (B) Effect of pH on labeling of Bt and Bx GH99 enzymes with 4 or 5. (C) Labeling of wild-
type and mutant BxGH99 with 4 or 5 (left or right, respectively) for 5, 15 or 30 minutes. (D) Effect of denaturation with 1% (w/v) SDS and boiling on labeling
of Bt and Bx GH99 enzymes (left and right, respectively) with 4 or 5. The marker is annotated with an asterisk (*).
Figure 3. (A) Schematic representation of processing of human a-galactosidase GLA by
GH99 endomannosidase. GLA is pre-labeled by fluorescent TB340, and contains high-
mannose N-glycans which can be truncated by endomannosidase, resulting in a decrease
in GLA molecular weight. Activity-based labeling of endomannosidase by spiro-epoxygly-
cosides 4 or 5 (prior to incubation with GLA) blocks its activity, and is therefore unable
to process GLA. (B) BtGH99 wild-type demannosylates GLA, causing a shift in molecular
weight for the protein bands. Pre-labeling BtGH99 wild-type with 4 or 5 abrogates GLA
demannosylation. Endo-H cleaves high-mannose structures, PNGase-F cleaves full N-
linked glycan (leaving Asp-GlcNAc). (C) BxGH99 wild-type demannosylates GLA, while
BxGH99 pre-labeled with 4 or 5 is unable to do so. BxGH99 active-site mutants E333Q
and E3336Q are unable to process GLA. (D) Fluorescent labeling of BtGH99 (top) and
BxGH99 (bottom) by 4 or 5 competed by different concentrations of 17, 18, ManIFG (2)
and yeast mannan. The marker is annotated with an asterisk (*).
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(lane 5), which cleaves most N-glycans leaving Asn, results in a
band of a lower molecular weight, most likely as a result of
complete deglycosylation of all three N-glycans. When BtGH99
was pre-incubated with 4 or 5, demannosylation of TB340-la-
beled GLA was mostly inhibited (lane 3), indicating that bind-
ing of 4 and 5 occurs in the BtGH99 active site. An identical ex-
periment was conducted with BxGH99 wildtype and the E333Q
and E336Q mutant enzymes (Figure 3C). Similar to BtGH99,
wildtype BxGH99 is able to process the N-glycans decorating
the surface of the enzyme, giving rise to a shift in molecular
weight (lane 2), similar to processing by Endo-H (lane 8). Pre-
incubation of WT BxGH99 by 4 or 5, prior to consecutive incu-
bation with TB340-labeled GLA resulted in an observed ab-
sence of glycan processing (lane 3), indicating that binding of
4 and 5 abrogates enzymatic activity. Interestingly, while mu-
tants E333Q and E336Q are labeled by spiro-epoxyglycosides 4
and 5 after prolonged reaction times, they are evidently
unable to process TB340-labeled GLA (lanes 4–7).
Finally, the inhibitory potencies of 2, 17, 18 and yeast
mannan from S. cerevisiae (an a-1,6-linked mannose backbone
branched with a-1,2 and a-1,3 mannoses)[38] towards BtGH99
were investigated using spiro-epoxyglycoside 5 as fluorescent
read-out (Figure 3D). The enzyme was first pre-incubated with
the competitor for 30 min at 37 8C, followed by labeling with
1 mm 5. Compounds 17 and 18 both show a concentration-de-
pendent competition of fluorescent labeling in the range of
10-1,000 mm, although full competition with labeling could not
be achieved under these conditions. Similarly, the azasugar
ManIFG (2) gave concentration-dependent competition but
again full competition was not achieved. However, pre-incuba-
tion by yeast mannan achieved full competition with labeling,
suggesting that processing of spiro-epoxyglycoside 5 by
BtGH99 endomannanase is specific and activity based. A similar
competition experiment was performed for BxGH99, and it was
shown that while pre-incubation with 17 did not fully abrogate
labeling, pre-incubation with 1000 mm of 18 provided full com-
petition, possibly hinting at a slight preference for a mannosyl
residue in subsite @2. Additionally, yeast mannan showed con-
centration dependent (albeit incomplete) competition, and
azasugar 2 fully competed with labeling at 1,000 mm, suggest-
ing that processing of spiro-epoxyglycoside 5 by BxGH99 is
specific and activity-based.
Discussion
Epoxide-based probes have been investigated as mechanism-
based inhibitors of a range of glycosidases. Early work led to
the development of epoxyalkyl glycosides,[39] which were ini-
tially proposed as reagents that could specifically label the nu-
cleophile of retaining glycosidases, however X-ray crystallogra-
phy later revealed labelling of both acid/base and nucleophile
residues.[40] In one classic study, conduritol C epoxide, which
was originally believed to label the nucleophile of E. coli LacZ
b-galactosidase, was subsequently shown to covalently label
the acid/base catalyst.[41] Work from our laboratory has investi-
gated related pyranose-mimicking cyclophellitol epoxides and
aziridines and shown that these typically exhibit excellent se-
lectivity for labelling the nucleophile of assorted a- and b-gly-
cosidases.[42] We have shown that introduction of a reporter
tag (e.g. biotin or a fluorescent dye) onto these small molecule
inhibitors affords chemical probes that enable quantification of
activity,[43,44] and have distinct advantages over techniques
such as transcription analysis and antibody-based detection.
We report here the first activity-based probes for detection of
GH99 enzymes, which were designed based on the proposed
mechanism of this enzyme. In this proposed mechanism a 1,2-
anhydro-epoxide intermediate is formed by general base as-
sisted deprotonation of O2 by a carboxylate residue.[23] Our
design strategy includes a reactive C2 spiro-epoxide that can
potentially covalently label the general base (acting as a nucle-
ophile), and includes a fluorescent label for visualization. Gel-
based analysis of labelled bacterial GH99 endo-1,2-a-mannan-
ases demonstrated concentration dependent labelling which
occurs in a pH dependent manner consistent with the pH opti-
mum of enzyme activity. Labelling could be competed by vari-
ous substrates and inhibitors, providing evidence that it is
active-site directed. While mutation of the key general base
and general acid residues inactivated the enzyme towards
processing of natural substrate N-glycans in GLA, the mutants
could be labelled with the spiro-epoxyglycosides, albeit with
reduced potency. Collectively, our data suggests that these
spiro-epoxides do result in labelling at the active site,
presumeably through the catalytic general base. However, the
high reactivity of the primary epoxide means that labelling is
most likely not exclusive at a single residue. While endo-1,2-a-
mannanase has a preference for mannosyl residues at the @2
binding subsite, there was minimal differences in the efficiency
of labelling for spiro-epoxides bearing either a mannosyl or
glucosyl residue. We believe these compounds represent an
important first step in devising probes that take advantage of
the unique mechanism proposed for this family. Future studies
will seek to better understand the mode of labelling by identi-
fying the covalently labelled residue(s) by X-ray crystallography
or MS based techniques. By analogy to previously described
irreversible cyclophellitol activity-based probes,[43] we propose
these fluorescent spiro-epoxyglycosides could ultimately lead
to chemical tools for functional investigation of GH99 endo-
1,2-a-mannosidase/mannanases, both as isolated species and
in tissue extracts.
Experimental Section
Chemicals were purchased from Acros, Sigma Aldrich, Biosolve,
VWR, Fluka, Merck and Fisher Scientific and used as received
unless stated otherwise. Tetrahydrofuran (THF), N,N-dimethylform-
amide (DMF) and toluene were stored over molecular sieves
before use. All reactions were performed under an argon atmos-
phere unless stated otherwise. TLC analysis was conducted using
Merck aluminum sheets (Silica gel 60 F254) with detection by UV ab-
sorption (254 nm), by spraying with a solution of
(NH4)6Mo7O24·4H2O (25 gL
@1) and (NH4)4Ce(SO4)4·2H2O (10 gL
@1) in
10% sulfuric acid, followed by charring at &150 8C. Column chro-
matography was performed using Screening Device b.v. silica gel
(particle size of 40–63 mm, pore diameter of 60 a) with the indicat-
ed eluents. For reversed-phase HPLC purifications an Agilent Tech-
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nologies 1200 series instrument equipped with a semi-preparative
column (Gemini C18, 250V10 mm, 5 mm particle size, Phenomen-
ex) was used. 1H NMR and 13C NMR spectra were recorded on a
Breker AV-400 (400 and 101 MHz, respectively) or a Breker DMX-
600 (600 and 151 MHz, respectively) spectrometer in the given sol-
vent. Chemical shifts are given in ppm (d) relative to the residual
solvent peak or tetramethylsilane (0 ppm) as internal standard.
High-resolution mass spectrometry (HRMS) analysis was performed
with a LTQ Orbitrap mass spectrometer (Thermo Finnigan),
equipped with an electronspray ion source in positive mode
(source voltage 3.5 kV, sheath gas flow 10 mLmin@1, capillary tem-
perature 250 8C) with resolution R=60000 at m/z 400 (mass range
m/z 150–2000) and dioctyl phthalate (m/z 391.28428) as lock mass.
The high-resolution mass spectrometer was calibrated prior to
measurements with a calibration mixture (Thermo Finnigan).
ManIFG was prepared as previously reported.[18] Recombinant ex-
pression of B. thetaiotaomicron (Bt) and B. xylanisolvens (Bx) GH99
was achieved as previously described.[23] Recombinant a-galactosi-
dase (GLA) was purchased from Genzyme (Cambridge, MA, USA).
The a-galactosidase ABP TB340 was synthesized as described earli-
er.[37] Yeast mannan from S. cerevisiae was purchased from Sigma.
Synthesis and characterization
(4aR,6S,7S,8R,8aS)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-hy-
droxyhexahydropyrano[3,2-d][1,3,2]dioxasilin-7-yl benzoate (7):
Compound 6[45] (1.00 g, 3.80 mmol) was co-evaporated with dry
toluene and dissolved in dry DMF (38 mL). The resulting solution
was cooled to @50 8C and SitBu2(OTf)2 (1.11 mL, 3.42 mmol, 0.9 EQ)
and 2,6-lutidine (0.44 mL, 3.80 mmol) were added. The reaction
was stirred at @50 8C for 30 minutes and subsequently quenched
with brine (400 mL). The aqueous layer was extracted with Et2O
(4V100 mL). The combined organic layers were washed with 1m
aqueous HCl (2V100 mL), H2O (100 mL), and brine and dried over
Na2SO4. The solvents were removed under reduced pressure and
the crude product was purified by gradient column chromatogra-
phy (EtOAc/pentane, 1:4 to 1:2). The 4,6-silydene product was ob-
tained as white solid (970 mg, 70%). 1H NMR (400 MHz, CDCl3): d=
4.81 (d, J=1.4 Hz, 1H), 4.11 (dd, J=10.0, 5.0 Hz, 1H), 4.07–4.00 (m,
2H), 3.96 (t, J=10.2 Hz, 1H), 3.86–3.76 (m, 2H), 3.69 (td, J=10.0,
5.0 Hz, 1H), 3.50 (ddd, J=10.0, 6.3, 5.2 Hz, 1H), 3.40 (td, J=6.6,
2.0 Hz, 2H), 1.94–1.82 (m, 2H), 1.06 (s, 9H), 1.00 ppm (s, 9H).
13C NMR (101 MHz, CDCl3): d=166.0, 133.4, 129.9, 129.7, 128.5,
98.1, 75.2, 72.0, 70.2, 67.4, 66.6, 64.6, 48.2, 28.8, 27.4, 27.0, 22.8,
20.0 ppm. IR (neat): n˜=3524, 2934, 2886, 2097, 1732, 1717, 1558,
1472, 1267, 1095, 1072, 1026, 885, 826, 710, 654 cm@1. [a]20D (c 0.1,
DCM): @16. HRMS (ESI) m/z : [M+Na]+ calcd for C24H37N3O7SiNa
530.22930, found 530.22907. The 4,-6-silydene compound (889 mg,
2.20 mmol) was dissolved in trimethyl orthobenzoate (5.7 mL) and
CSA (102 mg, 0.44 mmol) was added. The reaction was stirred for
2 hours at room temperature and cooled to 0 8C. Aqueous AcOH
(50%, 20 mL) was added and the mixture was stirred overnight
while the cooling bath was allowed to reach room temperature.
The solution was poured into saturated aqueous NaHCO3 (50 mL)
and the water layer was extracted with CH2Cl2 (3V50 mL). The
combined organic layers were washed with NaHCO3 (50 mL) and
dried over MgSO4. The solvents were removed under reduced pres-
sure and the crude product was purified by gradient column chro-
matography (EtOAc/pentane, 1:99 to 1:10). The title product was
obtained as colorless oil (922 mg, 82%). 1H NMR (400 MHz, CDCl3):
d=8.15–7.98 (m, 2H), 7.63–7.54 (m, 1H), 7.51–7.41 (m, 2H), 5.42
(dd, J=3.4, 1.6 Hz, 1H), 4.88 (d, J=1.4 Hz, 1H), 4.23–4.06 (m, 3H),
3.99 (t, J=10.2 Hz, 1H), 3.86–3.76 (m, 2H), 3.59–3.49 (m, 1H), 3.43
(t, J=6.6 Hz, 2H), 1.99–1.81 (m, 2H), 1.09 (s, 9H), 1.02 ppm (s, 9H).
13C NMR (101 MHz, CDCl3): d=166.0, 133.4, 129.9, 129.7, 128.5,
98.1, 75.2, 72.0, 70.2, 67.4, 66.6, 64.6, 48.2, 28.8, 27.4, 27.0, 22.8,
20.0 ppm. IR (neat): n˜=3524, 2934, 2886, 2097, 1732, 1717, 1558,
1472, 1267, 1095, 1072, 1026, 885, 826, 710, 654 cm@1. [a]20D (c 0.1,
DCM): @16. HRMS (ESI) m/z : [M+Na]+ calcd for C24H37N3O7SiNa
530.22930, found 530.22907.
(4aR,6S,7R,8S,8aR)-2,2-Di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)-6-(phenylthio)hexahydropyrano[3,2-d][1,3,2]dioxasiline
(9): Compound 8[27] (2.6 g, 9.5 mmol) was dissolved in dry DMF
(100 mL) under Ar-atmosphere. The mixture was cooled to @50 8C
and 2,6-lutidine (3.3 mL, 28.5 mmol) and SitBu2(OTf)2 (3.4 mL,
10.5 mmol) was added. The reaction was stirred for 2 hours at
@50 8C and subsequently quenched with H2O (100 mL). The water
layer was extracted with EtOAc (3V100 mL). The organic layers
were combined and washed with H2O (2V200 mL) and brine
(200 mL) and dried over MgSO4. The solvents were removed under
reduced pressure and the crude product was purified by gradient
column chromatography (EtOAc/pentane, 1:4 to 1:2). The 4,6-sily-
dene product was obtained as a white solid (3.58 g, 91%). 1H NMR
(400 MHz, CDCl3): d=7.57–7.46 (m, 2H), 7.38–7.28 (m, 3H), 4.60 (d,
J=9.7 Hz, 1H), 4.21 (dd, J=10.2, 5.1 Hz, 1H), 3.90 (t, J=10.2 Hz,
1H), 3.68 (t, J=9.0 Hz, 1H), 3.60 (t, J=8.7 Hz, 1H), 3.51–3.37 (m,
2H), 2.92 (s, 1H), 2.77 (s, 1H), 1.04 (s, 9H), 0.98 ppm (s, 9H).
13C NMR (101 MHz, CDCl3): d=132.9, 131.7, 129.1, 128.3, 88.6, 77.8,
76.4, 74.5, 71.8, 66.1, 27.4, 27.0, 22.7, 19.9. IR (neat): n˜=3241, 2932,
2858, 1695, 1471, 1058 cm@1. [a]20D (c 0.06, DCM): @57.0. HRMS (ESI)
m/z : [M+Na]+ calcd for C20H32O5SSiNa 435.16319, found
435.16315. The 4,6-silydene product (1.0 g, 2.42 mmol) was co-
evaporated with toluene (3V), dissolved in dry pyridine (5 mL) and
cooled to 0 8C. DMAP (30 mg, 0.24 mmol) and TBSOTf (3.33 mL,
14.5 mmol) were added and the mixture was heated to 60 8C and
stirred overnight. The mixture was carefully diluted with water
(25 mL) and extracted with DCM (3V 50 mL). The combined organ-
ic layers were washed with aq. 1m HCl (3V25 mL) and brine, dried
over Na2SO4, filtrated and concentrated. The crude product was
purified by gradient column chromatography (pentane/EtOAc,
400:1 to 200:1), affording the title product as a white solid (1.44 g,
93%). Analytical data were in accordance with those reported in
literature.[46]
(4aR,6R,7S,8S,8aR)-2,2-Di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)-6-(phenylthio)hexahydropyrano[3,2-d][1,3,2]dioxasiline
(11): The 4,6-silydene compound was prepared from 10[28] (4.9 g,
18 mmol) as described for the preparation of 9 to afford the prod-
uct (6.6 g, 89%) as a white solid. 1H NMR (400 MHz, CDCl3): d=7.52
@7.20 (m, 5H), 5.53 (s, 1H), 4.30 (d, J=3.1 Hz, 1H), 4.24 (td, J=
10.0, 5.0 Hz, 1H), 4.15–4.08 (t, J=9.4 Hz, 1H), 4.05 (dd, J=10.0,
5.0 Hz, 1H), 3.96 (t, J=10.1 Hz, 1H), 3.87 (dd, J=9.1, 3.3 Hz, 1H),
2.67 (brs, 2xOH), 1.05 (s, 9H), 1.03 ppm (s, 9H). 13C NMR (101 MHz,
CDCl3): d=133.9, 131.5, 129.3, 127.7, 87.8, 75.0, 72.4, 72.1, 67.9,
66.2, 27.6, 27.2, 22.8, 20.2 ppm. IR (neat): n˜=3384, 2932, 2858,
1474, 1064 cm@1. [a]20D (c 0.4, DCM): +227. HRMS (ESI) m/z : [M+
Na]+ calcd for C20H32O5SSiNa 435.16319, found 435.16301. The title
product was prepared from the 4,6-silydene compound (6.6 g,
16 mmol) as described for the preparation of 9 to afford the prod-
uct (9.3 g, 91%) as a pale yellow oil which crystallized at @20 8C.
1H NMR (400 MHz, CDCl3): d=7.48–7.25 (m, 5H), 5.29 (d, J=1.5 Hz,
1H), 4.28 (t, J=9.0 Hz, 1H), 4.19 (m, 1H), 4.17–4.11 (m, 1H), 4.11–
4.08 (m, 1H), 3.96 (t, J=9.7 Hz, 1H), 3.87 (dd, J=8.9, 2.5 Hz, 1H),
1.09 (s, 9H), 1.07 (s, 9H), 0.99 (s, 9H), 0.92 (s, 9H), 0.21 (s, 3H), 0.18
(s, 3H), 0.14 (s, 3H), 0.07 ppm (s, 3H). 13C NMR (101 MHz, CDCl3):
d=134.9, 131.3, 129.3, 127.4, 89.9, 75.0, 74.6, 73.0, 69.6, 67.1, 27.8,
27.3, 26.3, 25.8, 22.9, 20.2, 18.5, 18.2, @3.9, @4.1, @4.4, @4.4 ppm.
IR (neat): n˜=2931, 2857, 1471, 1250, 1096 cm@1. [a]20D (c 1.0, DCM):
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+91. HRMS (ESI) m/z : [M+H]+ calcd for C32H61O5SSi3 641.35420,
found 641.36460.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-yl benzoate (12g): Com-
pound 9 (2.00 g, 3.12 mmol) and compound 7 (1.58 g, 3.12 mmol)
were combined and co-evaporated with toluene (3V). The mixture
was dissolved in dry CH2Cl2 (20 mL) and stirred with activated 4A
MS for 30 minutes at room temperature. The reaction was cooled
to @50 8C and NIS (842 mg, 3.74 mmol) and TMSOTf (68 mL,
0.37 mmol) were added. The reaction mixture was warmed to
@40 8C, stirred for 1 hour and subsequently neutralized with NEt3
(2 mL). The mixture was diluted with CH2Cl2 (200 mL) and washed
with saturated aqueous Na2SO3 (2V100 mL), H2O (100 mL) and
subsequently dried over MgSO4. The solvents were removed under
reduced pressure and the crude product was purified by gradient
column chromatography (EtOAc/pentane, 1:50 to 1:40). The title
product was obtained as a white foam (2.98 g, 92%). 1H NMR
(400 MHz, CDCl3): d=8.08 (d, J=7.3 Hz, 2H), 7.59 (t, J=7.4 Hz, 1H),
7.47 (t, J=7.7 Hz, 2H), 5.49 (s, 1H), 5.16 (d, J=2.9 Hz, 1H, H-1
“donor”), 4.86 (s, 1H, H-1 “acceptor”), 4.44 (t, J=9.4 Hz, 1H), 4.22–
4.15 (m, 2H, H-3), 4.04 (t, J=10.2 Hz, 1H), 3.95–3.79 (m, 3H), 3.75–
3.66 (m, 2H), 3.61 (t, J=8.4 Hz, 1H), 3.54 (dt, J=10.2, 5.7 Hz, 1H),
3.49–3.41 (m, 2H), 1.91 (dq, J=13.5, 6.9 Hz, 1H), 1.13 (s, 9H), 1.04
(s, 9H), 1.03 (s, 9H), 0.97 (s, 9H), 0.91 (s, 9H), 0.79 (s, 9H), 0.17 (s,
3H), 0.05 (s, 3H), 0.03 ppm (s, 3H). 13C NMR (101 MHz, CDCl3): d=
165.4, 133.2, 129.9, 129.6, 128.5, 98.1, 97.9, 78.6, 75.2, 74.3, 73.4,
72.6, 71.1, 67.8, 67.8, 66.9, 66.6, 64.4, 48.1, 28.9, 27.5, 27.1, 27.0,
26.4, 26.2, 22.7, 22.7, 20.0, 20.0, 18.1, 18.0, @3.2, @3.5, @3.6,
@4.4 ppm. 13C-HMBC-GATED NMR (101 MHz, CDCl3): d=98.1
(JC1,H1=170.6 Hz, C1 “donor”), 97.9 (JC1,H1=172.1 Hz, C1 “acceptor”).
IR (neat): n˜=2966, 2859, 2093, 1732, 1472, 1260, 1096, 1069, 1045,
827 cm@1. [a]20D (c 0.1, DCM): +20. HRMS (ESI) m/z : [M+Na]
+ calcd
for C50H91N3O12Si4+Na 1060.55720, found 1060.55694.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-yl benzoate (12m): This
compound was prepared from 11 (378 mg, 0.59 mmol) and 7
(299 mg, 0.59 mmol) as described for the preparation of 12g, to
afford the title product (538 mg, 88%) as a pale yellow oil. 1H NMR
(400 MHz, CDCl3): d=8.02 (m, 2H), 7.62–7.53 (m, 1H), 7.45 (t, J=
7.7 Hz, 2H), 5.34 (dd, J=3.5, 1.6 Hz, 1H), 4.96 (d, J=1.9 Hz, 1H),
4.82 (d, J=1.4 Hz, 1H), 4.28 (t, J=9.5 Hz, 1H), 4.15 (m, 3H), 4.08
(dd, J=9.4, 3.6 Hz, 1H), 4.02–3.93 (t, J=10.3 Hz, 1H), 3.90–3.77 (m,
4H), 3.77–3.67 (m, 2H), 3.57–3.37 (m, 3H), 2.02–1.77 (m, 2H), 1.09
(s, 9H), 1.04–1.00 (s, 9H), 1.00 (s, 9H), 0.95–0.89 (m, 9H), 0.87–0.82
(m, 9H), 0.82–0.76 (m, 9H), 0.07 (s, 3H), 0.00 (s, 3H), @0.13 (s, 3H),
@0.17 ppm (s, 3H). 13C NMR (101 MHz, CDCl3): d=165.5, 133.4,
130.0, 129.7, 128.6, 103.4, 98.2, 75.2, 75.1, 74.0, 73.6, 72.4, 71.8,
69.5, 67.7, 67.5, 67.1, 64.8, 48.4, 29.0, 27.9, 27.7, 27.2, 27.2, 26.2,
25.8, 22.9, 22.9, 20.1, 19.9, 18.4, 18.2, @4.3, @4.4, @4.4, @4.7 ppm.
13C-HMBC-GATED NMR (101 MHz, CDCl3): d=103.4 (JC1,H1=172.1 Hz,
C1 “donor”), 98.2 ppm (JC1,H1=172.5 Hz, C1 “acceptor”). IR (neat):
n˜=2931, 2858, 20998, 1729, 1472, 1226, 1096, 1068 cm@1. [a]20D (c
0.4, DCM): +1. HRMS (ESI) m/z : [M+H]+ calcd for C50H92N3O12Si4
1038.57526, found 1038.57587.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-ol (13g): Compound 12g
(610 mg, 0.59 mmol) was co-evaporated with toluene (3V) and dis-
solved in a mixture of DCM/MeOH (9 mL, 1:1). NaOMe (30 wt%,
560 mL) was added and the reaction mixture was stirred for 24 h.
The reaction was neutralized with AcOH and the solvents were re-
moved under reduced pressure. The crude product was purified by
gradient column chromatography (EtOAc/pentane, 1:11 to 1:8).
The title product was obtained as a white foam (519 mg, 95%).
1H NMR (400 MHz, CDCl3): d=5.34 (d, J=3.1 Hz, 1H), 4.81 (d, J=
0.7 Hz, 1H), 4.29 (t, J=9.3 Hz, 1H), 4.10–4.02 (m, 2H), 3.98 (t, J=
10.3 Hz, 1H), 3.95 (s, 1H), 3.88 (dd, J=9.2, 3.3 Hz, 1H), 3.86–3.76
(m, 3H), 3.76–3.66 (m, 3H), 3.58 (dd, J=8.2, 3.1 Hz, 1H), 3.54–3.47
(m, 1H), 3.38 (td, J=6.5, 1.7 Hz, 2H), 3.00 (s, 1H, OH), 1.94–1.78 (m,
2H), 1.05 (s, 9H), 1.04 (s, 9H), 1.00 (s, 9H), 0.98 (s, 9H), 0.93 (s, 9H),
0.92 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.09 ppm (s, 3H).
13C NMR (101 MHz, CDCl3): d=99.7, 97.4, 78.7, 75.1, 74.6, 74.5, 74.3,
71.1, 67.6, 67.4, 67.0, 66.4, 64.4, 48.4, 29.0, 27.6 (3V), 27.5 (3V), 27.2
(3V), 27.1 (3V), 26.4 (3V), 26.4 (3V), 22.9, 22.7, 20.1, 20.1, 18.3, 18.3,
@3.1, @3.3, @3.4, @3.9 ppm. IR (neat): n˜=2931, 2856, 2099, 1472,
1252, 1132, 1095, 1069, 1043, 868, 827, 772, 654 cm@1. [a]20D (c 0.1,
DCM): +44. HRMS (ESI) m/z : [M+Na]+ calcd for C43H87N3O11Si4+Na
956.53099, found 956.53097.
(4aR,6S,7S,8R,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)hexa-
hydropyrano[3,2-d][1,3,2]dioxasilin-7-ol (13m): This compound
was prepared from 12m (501 mg, 0.48 mmol) as described for the
preparation of 13g to afford the title product (386 mg, 86%) as a
colorless oil. 1H NMR (400 MHz, CDCl3): d=5.00 (d, J=1.9 Hz, 1H),
4.79 (d, J=1.1 Hz, 1H), 4.17 (t, J=9.2 Hz, 1H), 4.11 (m, 3H), 3.99–
3.88 (m, 4H), 3.88–3.82 (m, 2H), 3.82–3.77 (m, 1H), 3.77–3.62 (m,
2H), 3.49 (m, 1H), 3.40 (td, J=6.5, 3.1 Hz, 1H), 2.37–2.03 (brs, OH),
1.97–1.77 (m, 2H), 1.04 (m, 18H), 0.99 (s, 9H), 0.97 (s, 9H), 0.93 (s,
9H), 0.86 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H), 0.10 (s, 3H), 0.02 ppm (s,
3H). 13C NMR (101 MHz, CDCl3): d=103.2, 99.6, 77.7, 74.5, 74.1,
73.3, 72.4, 71.5, 69.6, 67.4, 67.33, 66.8, 64.5, 48.4, 28.9, 27.8, 27.6,
27.2, 27.1, 26.3, 25.8, 22.9, 22.7, 20.1, 18.6, 18.2, @3.9, @4.1, @4.3,
@4.6. ppm IR (neat): n˜=2930, 2858, 2098, 1472, 1250, 1096,
1031 cm@1. [a]20D (c 0.4, DCM): +32. HRMS (ESI) m/z : [M+H]
+ calcd
for C43H88N3O11Si4 934.54904, found 934.54959.
(4aR,6S,8S,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydropyrano[3,2-d][1,3,2]dioxasilin-7(6H)-one (14g): Compound
13g (2.20 g, 2.36 mmol) was co-evaporated with dry toluene (3V)
and dissolved in dry CH2Cl2 (65 mL). Dess–Martin periodinane
(2.00 g, 4.71 mmol) was added and the mixture was stirred over-
night. Celite was added and the solvents were removed under re-
duced pressure. The product was purified by gradient column
chromatography (EtOAc/pentane, 1:70 to 1:4). The title product
was obtained as a white foam (2.15 g, 98%). 1H NMR (400 MHz,
CDCl3): d=5.18 (d, J=2.8 Hz, 1H), 4.73–4.72 (m, 2H), 4.24–4.02 (m,
5H), 4.02–3.90 (m, 1H), 3.90–3.73 (m, 3H), 3.67 (t, J=8.6 Hz, 1H),
3.62–3.54 (m, 2H), 3.40 (t, J=6.6 Hz, 2H), 1.94–1.81 (m, 2H), 1.06 (s,
9H), 1.04 (s, 9H), 1.02 (s, 9H), 0.98 (s, 9H), 0.93 (s, 9H), 0.92 (s, 9H),
0.17 (s, 3H), 0.12 (s, 3H), 0.11 (s, 3H), 0.08 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=196.2, 100.2, 98.2, 80.0, 78.9, 78.7, 74.9, 73.9,
67.49, 67.45, 67.0, 66.0, 65.3, 48.0, 27.5, 27.4 (3V), 27.1 (3V), 27.0
(3V), 26.5 (3V), 26.41 (3V), 22.7, 22.6, 20.0, 20.0, 18.3, 18.1, @3.0,
@3.5, @3.7, @3.9 ppm. IR (neat): n˜=2932, 2859, 2099, 1757, 1474,
1387, 1362, 1252, 1161, 1093, 1070, 1043, 866, 827, 775, 652 cm@1.
[a]20D (c 0.1, DCM): +50. HRMS (ESI) m/z : [M+Na]
+ calcd for
C43H85N3O11Si4+Na 954.51534, found 954.51535.
(4aR,6S,8S,8aR)-6-(3-Azidopropoxy)-2,2-di-tert-butyl-8-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
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silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydropyrano[3,2-d][1,3,2]dioxasilin-7(6H)-one (14m): This com-
pound was prepared from 13m (355 mg, 0.38 mmol) as described
for the preparation of 14g to afford the title product (340 mg,
96%) as a yellow oil. 1H NMR (400 MHz, CDCl3): d=4.81 (d, J=
1.9 Hz, 1H), 4.75 (s, 1H), 4.45 (d, J=9.1 Hz, 1H), 4.31–4.19 (m, 2H),
4.18–4.12 (t, J=9.2 Hz, 1H), 4.12–3.98 (m, 4H), 3.97–3.88 (m, 2H),
3.88–3.78 (m, 2H), 3.61–3.52 (dt, J=9.9, 5.4 Hz, 1H), 3.41 (t, J=
6.5 Hz, 2H), 2.00–1.76 (m, 2H), 1.05 (s, 9H), 1.05 (s, 9H), 1.04 (s,
9H), 1.00 (s, 9H), 0.93 (s, 9H), 0.86 (s, 9H), 0.15 (s, 3H), 0.12 (s, 3H),
0.09 (s, 3H), 0.01 ppm (s, 3H). 13C NMR (101 MHz, CDCl3): d=195.8,
103.4, 100.3, 82.2, 79.5, 74.4, 73.3, 72.1, 68.9, 67.3, 67.1, 66.6, 65.3,
48.0, 28.8, 27.6, 27.4, 27.1, 27.0, 26.2, 25.7, 22.8, 22.7, 20.1, 20.0,
18.4, 18.1, @4.0, @4.2, @4.5, @4.7 ppm. IR (neat): n˜=2933, 2858,
2087, 1755, 1471, 1254, 1155 cm@1. [a]20D (c 0.4, DCM): +47. HRMS
(ESI) m/z : [M+H]+ calcd for C43H86N3O11Si4 932.53339, found
932.53363.
(2S,4a’R,6’S,8’S,8a’R)-6’-(3-Azidopropoxy)-2’,2’-di-tert-butyl-8’-
(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]dioxasiline]
(15g) and (2R,4a’R,6’S,8’S,8a’R)-6’-(3-azidopropoxy)-2’,2’-di-tert-
butyl-8’-(((4aR,6R,7R,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyl-
dimethylsilyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-
yl)oxy)tetrahydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]di-
oxasiline] (16g): Method A: dimethyl sulfonium methylide: A 1m
solution of dimsyl-sodium was prepared from sodium hydride
(60 wt%, 200 mg, 5 mmol) in dry DMSO (2.5 mL) and heating this
mixture to 70 8C for 1 h. The olive-green solution was cooled to
room temperature and diluted with dry THF (2.5 mL). A fraction
(0.12 mL, 0.19 mmol) of this mixture was added to a dried flask
and cooled on an ice-salt bath. Then, a solution of trimethylsulfoni-
um iodide (26.3 mg, 0.129 mmol) in dry DMSO (0.43 mL) and dry
THF (0.4 mL) was added drop wise and the mixture was stirred for
5 minutes. Then, compound 14g (100 mg, 0.11 mmol, co-evaporat-
ed with toluene (3V) beforehand) in dry THF (0.64 mL) was added
and the mixture was stirred for 30 minutes. The mixture was dilut-
ed with water (20 mL) and extracted with Et2O/pentane (2:1, 4x
15 mL). The combined organic layers were washed with water
(20 mL), dried over Na2SO4, filtrated and concentrated. The crude
product was purified by gradient column chromatography (pen-
tane/EtOAc, 60:1 to 50:1) to afford solely product 15g (51 mg,
50%) as an oil.
Method B: dimethyl sulfoxonium methylide: Trimethylsulfoxonium
iodide (37.8 mg, 0.172 mmol) was suspended in dry THF (2 mL)
and cooled to 0 8C. nButyllithium (2m in pentane, 80 mL,
0.16 mmol) was added and the mixture was heated to 60 8C. Com-
pound 14g (100 mg, 0.11 mmol) was co-evaporated with toluene
(3V), dissolved in dry THF (1 mL) and added drop wise to the ylide
solution. After 10 minutes, the mixture was cooled to room tem-
perature and quenched with MeOH (0.5 mL). The mixture was
evaporated and the crude product was purified by gradient
column chromatography (pentane/EtOAc, 60:1) to give a mixture
of compounds 15g and 16g (90 mg, ratio 15g :16g 1:5, total yield
88%) as a colorless oil.
Method C: diazomethane: To a glass tube were added aq. KOH
(40%, 5 mL) and Et2O (20 mL) and this mixture was cooled to 0 8C.
Then, 1-methyl-3-nitro-1-nitrosoguanidine (2.9 g, 10 mmol) was
added in portions with swirling. A fraction (2 mL) of the bright
yellow ether layer was added drop-wise to a solution of compound
14g (100 mg, 0.11 mmol) in EtOH (3 mL) at 0 8C. After stirring for
10 minutes, acetic acid (glacial) was added drop wise until the
yellow mixture turned colorless. The mixture was concentrated and
co-evaporated with toluene (3V). The crude products were purified
by column chromatography (pentane/acetone, 150:1), affording
compound 15g and 16g (79 mg, ratio 15g :16g 1:1, total yield
78%). Data for compound 15g (equatorial methylene): 1H NMR
(400 MHz, CDCl3): d=5.33 (d, J=2.9 Hz, 1H), 4.27–4.15 (m, 3H),
4.18 (s, 1H), 4.10–4.01 (m, 2H), 4.00–3.95 (t, J=10.1 Hz, 1H), 3.92–
3.76 (m, 3H), 3.75–3.59 (m, 4H), 3.50–3.35 (m, 3H), 3.15 (d, J=
5.1 Hz, 1H), 2.61 (d, J=5.1 Hz, 1H), 1.86 (quintet, J=6.3 Hz, 2H),
1.04 (s, 9H), 1.04 (s, 9H), 0.98 (s, 18H), 0.91 (s, 9H), 0.90 (s, 9H),
0.13 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=102.5, 97.4, 79.3, 78.5, 76.0, 74.8, 68.7, 67.6,
67.1, 66.3, 64.2, 59.4, 48.3, 46.4, 29.9, 29.1, 27.6, 27.5, 27.2, 27.1,
26.3, 22.9, 22.7, 20.1, 18.4, 18.3, @3.6, @3.6, @4.0 ppm. IR (neat):
n˜=2930, 2858, 2099, 1472, 1252, 1091, 1043 cm@1. [a]20D (c 0.1,
DCM): +54. HRMS (ESI) m/z : [M+Na]+ calcd for C16H27N3O11Na
968.53099, found 968.53089.Data for compound 16g (axial methyl-
ene) 1H NMR (400 MHz, CDCl3): d=5.34 (d, J=3.0 Hz, 1H), 4.40–
4.22 (m, 2H), 4.09 (dd, J=10.4, 5.1 Hz, 2H), 4.04–3.93 (m, 3H),
3.87–3.76 (m, 4H), 3.66 (t, J=8.7 Hz, 1H), 3.56–3.39 (m, 4H), 3.23
(d, J=5.6 Hz, 1H), 2.63 (d, J=5.6 Hz, 1H), 1.89 (q, J=5.7 Hz, 2H),
1.07 (s, 18H), 1.05 (s, 9H), 1.02 (s, 9H), 0.96 (s, 9H), 0.95 (s, 9H),
0.16 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.10 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=101.2, 96.9, 79.7, 78.2, 74.7, 73.8, 67.7, 67.4,
66.9, 66.8, 66.1, 64.4, 58.3, 48.1, 48.0, 29.0, 27.6 (3V), 27.3 (3V), 27.2
(3V), 27.0 (3V), 26.5 (3V), 26.4 (3V), 22.8, 22.5, 20.1, 20.0, 18.2, 18.1,
@3.08, @3.38 (2V), @4.03 ppm. IR (neat): n˜=2934, 2858, 2320,
2094, 1095, 1043, 827, 773 cm@1. [a]20D (c 0.1, DCM): +98 (c 0.1,
DCM). HRMS (ESI) m/z : [M+H]+ calcd for C44H88N3O11Si4 946.54904,
found 946.54953.
(2S,4a’R,6’S,8’S,8a’R)-6’-(3-Azidopropoxy)-2’,2’-di-tert-butyl-8’-
(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyldimethyl-
silyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-yl)oxy)tetra-
hydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]dioxasiline]
(15m) and (2R,4a’R,6’S,8’S,8a’R)-6’-(3-azidopropoxy)-2’,2’-di-tert-
butyl-8’-(((4aR,6R,7S,8S,8aR)-2,2-di-tert-butyl-7,8-bis((tert-butyl-
dimethylsilyl)oxy)hexahydropyrano[3,2-d][1,3,2]dioxasilin-6-
yl)oxy)tetrahydro-6’H-spiro[oxirane-2,7’-pyrano[3,2-d][1,3,2]di-
oxasiline] (16m): Compounds 15m and 16m were prepared from
14m as described for the preparation of 15g and 16g, and could
be separated by careful column chromatography. Method A : Start-
ing from compound 14m (100 mg, 0.11 mmol), the product 16m
(54 mg, 53%) was obtained as the single product. Method B : Start-
ing from compound 14m (150 mg, 0.16 mmol), product 15m and
16m were obtained as a mixture (129 mg, 85%, ratio 15m :16m=
1:2). Method C: Starting from compound 14m (265 mg,
0.28 mmol), product 15m and 16m were obtained as a mixture
(263 mg, 98%, ratio 15m :16m=3:1). Data for 15m (equatorial
methylene): 1H NMR (400 MHz, CDCl3): d=5.12 (d, J=2.0 Hz, 1H),
4.28 (d, J=9.4 Hz, 1H), 4.22–4.14 (m, 3H), 4.14–4.05 (m, 2H), 4.00–
3.93 (t, J=10.3 Hz, 1H), 3.93–3.83 (m, 3H), 3.83–3.77 (m, 2H), 3.55–
3.43 (m, 2H), 3.40 (m, 2H), 3.08 (d, J=4.7 Hz, 1H), 2.67 (d, J=
4.7 Hz, 1H), 1.94–1.82 (m, 2H), 1.05 (s, 9H), 1.04 (s, 9H), 1.00 (s,
9H), 0.99 (s, 9H), 0.94–0.90 (m, 9H), 0.84 (s 9H), 0.14 (s, 3H), 0.11
(s, 3H), 0.10 (s, 3H), 0.00 ppm (s, 3H). 13C NMR (101 MHz, CDCl3):
d=102.2, 101.9, 78.2, 74.4, 73.4, 72.1, 70.8, 69.7, 68.2, 67.3, 66.5,
64.2, 58.9, 48.2, 46.6, 28.8, 27.7, 27.5, 27.01, 26.2, 25.6, 22.7, 22.6,
20.0, 19.9, 18.4, 18.1, @4.0, @4.2, @4.2, @4.8 ppm. IR (neat): n˜=
2929, 2098, 1741, 1251, 1161, 1099 cm@1. [a]20D (c 0.05, DCM): +38.
HRMS (ESI) m/z : [M+H]+ calcd for C44H88N3O11Si4 946.54904, found
946.54940. Data for compound 16m (axial methylene): 1H NMR
(400 MHz, CDCl3): d=4.94 (d, J=2.0 Hz, 1H), 4.28 (s, 1H), 4.25–4.11
(m, 5H), 3.98–3.85 (m, 6H), 3.85–3.75 (m, 3H), 3.48 (m, 3H), 2.98 (d,
J=5.3 Hz, 1H), 2.64 (d, J=5.3 Hz, 1H), 2.02–1.80 (m, 2H), 1.08 (s,
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9H), 1.06 (s, 9H), 1.03 (s, 9H), 1.01 (s, 9H), 0.96 (s, 9H), 0.87 (s, 9H),
0.15 (s, 3H), 0.14 (s, 3H), 0.11 (s, 3H), 0.03 ppm (s, 3H). 13C NMR
(101 MHz, CDCl3): d=102.1, 101.3, 79.0, 74.4, 73.5, 72.6, 68.7, 67.4,
67.2, 66.9, 64.5, 58.3, 48.2, 47.6, 28.9, 27.7, 27.7, 27.2, 27.1, 26.3,
25.7, 22.8, 22.8, 20.2, 20.1, 18.7, 18.2, @4.0, @4.1, @4.3, @4.6 ppm.
IR (neat): n˜=2931, 2098, 1741, 1251, 1159, 1097 cm@1. [a]20D (c 0.05,
DCM): +44. HRMS (ESI) m/z : [M+H]+ calcd for C44H88N3O11Si4
946.54904, found 946.54933.
(2R,3R,4S,5S,6R)-2-(((3R,4S,6R,7R,8S)-4-(3-Azidopropoxy)-7-hy-
droxy-6-(hydroxymethyl)-1,5-dioxaspiro[2.5]octan-8-yl)oxy)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (17): Compound
16g (145 mg, 0.153 mmol) was co-evaporated with toluene (3V)
and dissolved in dry THF (14.5 mL). TBAF (1m in THF, 2.3 mL,
2.3 mmol) was added and the mixture was stirred 5 days at room
temperature. The solution was eluted with THF over a small
Dowex-50WX4-200-Na+ packed column, concentrated and purified
by gradient column chromatography (EtOAc/MeOH, 19:1 to 9:1).
The product was dissolved in water and lyophilized to afford the
title compound as a white solid (64.8 mg, 97%). 1H NMR (400 MHz,
D2O): d=5.23 (d, J=3.8 Hz, 1H), 4.50 (s, 1H), 4.25 (d, J=9.0 Hz,
1H), 3.95–3.68 (m, 8H), 3.63–3.53 (m, 2H), 3.53–3.43 (m, 3H), 3.41–
3.34 (t, J=8 Hz, 1H), 3.17 (d, J=4.5 Hz, 1H), 2.87 (d, J=4.6 Hz, 1H),
1.97–1.85 ppm (m, 2H). 13C NMR (101 MHz, D2O): d=100.0, 99.2,
73.0, 72.9, 72.5, 71.7, 71.5, 70.91, 69.1, 64.8, 60.3, 60.2, 58.7, 48.4,
48.1, 27.8 ppm. IR (neat): n˜=3369, 2927, 2108, 1521, 1026 cm@1.
[a]20D (c 0.1, DCM): +174. HRMS (ESI) m/z : [M+NH4]
+ calcd for
C16H31N4O11 455.19838, found 455.19849.
(2R,3S,4S,5S,6R)-2-(((3R,4S,6R,7R,8S)-4-(3-azidopropoxy)-7-hy-
droxy-6-(hydroxymethyl)-1,5-dioxaspiro[2.5]octan-8-yl)oxy)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (18): This com-
pound was prepared from 16m (59 mg, 0.623 mmol) as described
for the preparation of 17 to afford the title product (20 mg, 74%)
as a white solid. 1H NMR (400 MHz, D2O): d=5.05 (d, J=1.6 Hz,
1H), 4.45 (s, 1H), 4.18 (d, J=9.3 Hz, 1H), 3.95 (dd, J=3.2, 1.8 Hz,
1H), 3.77 (m, 6H), 3.64 (m, 3H), 3.57–3.48 (m, 1H), 3.41 (t, J=
6.5 Hz, 2H), 3.10 (d, J=4.5 Hz, 1H), 2.81 (d, J=4.5 Hz, 1H), 1.95–
1.78 ppm (m, 2H). 13C NMR (101 MHz, D2O): d=101.0, 100.0, 73.3,
72.8, 72.5, 70.9, 70.4, 69.9, 66.3, 64.7, 60.8, 60.2, 58.7, 48.3, 48.0,
27.8 ppm. HRMS (ESI) m/z : [M+Na]+ calcd for C16H27N3O11
460.1538, found 460.1544.
1-(6-(((1-(3-(((3R,4S,6R,7R,8S)-7-Hydroxy-6-(hydroxymethyl)-8-
(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)-1,5-dioxaspiro[2.5]octan-4-yl)oxy)propyl)-1H-
1,2,3-triazol-4-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-2-
((1E,3E)-5-((Z)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-3H-indol-1-ium (4): Compound 17 (4.83 mg, 11.0 mmol) was dis-
solved in DMF (0.5 mL) and placed under Argon. Then the Cy5-
alkyne47 (6.1 mg, 11.0 mmol), aq. CuSO4 (0.1m, 44 mL, 4.4 mmol) and
aq. sodium ascorbate (0.1m, 44 mL, 4.4 mmol) were added and the
mixture was stirred overnight at room temperature. The product
was purified by HPLC (50 mm NH4CO3) to afford the title com-
pound as a blue solid (3.54 mg, 32%). 1H NMR (400 MHz, MeOD):
d=8.24 (t, J=13.0 Hz, 2H), 7.89 (s, 1H), 7.49 (d, J=7.4 Hz, 2H),
7.44–7.38 (m, 2H), 7.32–7.23 (m, 4H), 6.62 (t, J=12.4 Hz, 1H), 6.28
(d, J=13.7 Hz, 2H), 5.14 (d, J=3.8 Hz, 1H), 4.85 (s, 1H), 4.53 (t, J=
6.8 Hz, 2H), 4.42 (s, 2H), 4.32 (s, 1H), 4.16 (d, J=9.1 Hz, 1H), 4.10 (t,
J=7.4 Hz, 2H), 3.84–3.64 (m, 9H), 3.63 (s, 3H), 3.56 (t, J=9.3 Hz,
1H), 3.40 (dd, J=9.7, 3.8 Hz, 1H), 3.37–3.32 (1, 9H), 3.07 (d, J=
5.3 Hz, 1H), 2.70 (d, J=5.4 Hz, 1H), 2.25 (t, J=7.3 Hz, 2H), 2.23–
2.15 (m, 2H), 1.88–1.76 (m, 2H), 1.75–1.67 (m, 17H), 1.51–1.44 ppm
(m, 2H). 13C NMR (101 MHz, MeOD): d=180.3, 175.7, 175.4, 174.7,
155.5, 155.5, 146.1, 144.3, 143.6, 142.6, 142.5, 129.8, 129.7, 126.6,
126.3, 126.2, 124.7, 123.4, 123.3, 112.0, 111.9, 104.4, 104.3, 102.4,
101.8, 76.8, 75.1, 74.4, 74.0, 73.9, 73.0, 71.2, 65.3, 62.4, 62.4, 59.8,
50.6, 50.5, 48.4, 44.8, 36.5, 35.6, 31.5, 31.0, 28.1, 27.9, 27.8, 27.3,
26.4 ppm. HRMS (ESI) m/z : [M]+ calcd for C51H69N6O12 957.4968,
found 957.5005.
1-(6-(((1-(3-(((3R,4S,6R,7R,8S)-7-Hydroxy-6-(hydroxymethyl)-8-
(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)-1,5-dioxaspiro[2.5]octan-4-yl)oxy)propyl)-1H-
1,2,3-triazol-4-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-2-
((1E,3E)-5-((Z)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-3H-indol-1-ium (5): This compound was prepared from 18
(3.72 mg, 8.5 mmol) as described for the preparation of 4 to afford
the product (2.9 mg, 34%) as a blue solid. 1H NMR (600 MHz,
MeOD): d=8.24 (t, J=13.0 Hz, 2H), 7.90 (s, 1H), 7.49 (d, J=7.4 Hz,
2H), 7.44–7.39 (m, 2H), 7.28 (dt, J=16.4, 7.6 Hz, 4H), 6.62 (t, J=
12.4 Hz, 1H), 6.28 (d, J=13.7 Hz, 2H), 5.19 (d, J=1.3 Hz, 1H), 4.85
(s, 1H), 4.54 (t, J=6.8 Hz, 2H), 4.42 (s, 2H), 4.29 (s, 1H), 4.23 (d, J=
9.2 Hz, 1H), 4.10 (t, J=7.4 Hz, 3H), 3.90 (dd, J=3.2, 1.7 Hz, 1H),
3.85–3.68 (m, 9H), 3.66 (d, J=9.5 Hz, 1H), 3.63 (s, 3H), 3.60 (dd, J=
9.5, 3.3 Hz, 1H), 3.57–3.52 (m, 1H), 3.36–3.32 (m, 1H), 3.01 (d, J=
5.3 Hz, 1H), 2.68 (d, J=5.4 Hz, 1H), 2.26 (t, J=7.3 Hz, 2H), 2.20 (dq,
J=13.1, 6.7 Hz, 2H), 1.83 (m, 2H), 1.73 (s, 17H), 1.47 ppm (m, 2H).
13C NMR (150 MHz, MeOD): d=180.3, 175.7, 175.4, 174.7, 155.5,
155.5, 146.1, 144.3, 143.6, 142.6, 142.5, 129.8, 129.7, 126.6, 126.3,
126.2, 124.8, 123.4, 123.3, 112.1, 111.8, 104.4, 104.3, 102.6, 102.4,
74.7, 74.3, 74.1, 73.3, 72.7, 72.1, 68.2, 65.2, 62.7, 62.3, 59.9, 50.6,
50.5, 48.3, 44.8, 36.5, 35.7, 31.5, 31.1, 31.0, 28.1, 28.0, 27.8, 27.3,
26.4 ppm. HRMS (ESI) m/z : [M]+ calcd for C51H69N6O12 957.4968,
found 957.4995.
Labeling of BtGH99 and BxGH99 enzymes
To determine the detection limit, 400 ng recombinant B. thetaiotao-
micron (Bt) and B. xylanisolvens (Bx) GH99 enzymes were labeled in
150 mm McIlvaine buffer, pH 7.0 (citric acid-Na2HPO4) with 0.0001–
10 mm spiro-epoxyglycoside 4 or 5 for 1 h at 37 8C. The samples
were then denatured with 5V Laemmli buffer (50% (v/v) 1m Tris-
HCl, pH 6.8, 50% (v/v) 100% (v/v) glycerol, 10% (w/v) DTT, 10%
(w/v) SDS, 0.01% (w/v) bromophenol blue), boiled for 4 min at
100 8C, and separated by electrophoresis on 10% (w/v) SDS-PAGE
gel running continuously at 90 V.[43] Wet slab-gels were scanned on
fluorescence using a Typhoon FLA 9500 (GE Healthcare at lEX
532 nm and lEM 575 nm for ABP TB340; and at lEX 635 nm and lEM
665 nm for 4 and 5. The pH optimum was analyzed using 4 ng
enzyme incubated with 1 mm 4 or 5 dissolved in McIlvaine buffer,
pH 3–8, for 30 min at 37 8C. Time-dependent labeling of BxGH99
wild-type, E333Q and E336Q enzymes was assessed by incubating
400 ng for 5, 15 or 30 min with 1 mm 4 or 5 dissolved in McIlvaine
buffer, pH 7.0. The effect of denaturation was assessed on 4 ng
wild-type BtGH99 and BxGH99 by boiling for 4 min at 100 8C prior
to incubating with 1 mm 4 and 5 for 30 min at 37 8C. Competitive
ABPP assays utilized 4 ng BtGH99 and BxGH99 enzyme that was
pre-incubated with 10–1000 mm 17, 18 or ManIFG, or 0.3–
30 mgmL@1 yeast mannan (S. cerevisiae), at pH 7.0 for 30 min at
37 8C, followed by labeling with 1 mm 4 and 5 for 30 min at 37 8C.
Functional GLA assay
Recombinant a-galactosidase GLA was diluted 1:2 in 50 mm McIl-
vaine buffer, pH 4.6, and pre-labeled with 2 mm TB340 for 1 h at
37 8C. Subsequently, the mixture was diluted to 1:500 in 150 mm
McIlvaine buffer, pH 7.0. In parallel, 400 ng BxGH99 wild-type,
E333Q and E336Q were incubated in the presence or absence of
10 mm 4 or 5, dissolved in 150 mm McIlvaine buffer, pH 7.0, for 1 h
at 37 8C. Subsequently, the BxGH99 mixture (10 mL) was incubated
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with 10 mL TB340-labeled GLA for 8 h at 37 8C. Hereafter, samples
were denatured, separated on SDS-PAGE gel and visualized by fluo-
rescence scanning, as described above (vide supra). As control,
10 mL TB340-labeled GLA was treated by either Endo-H or PNGase-
F, following the manufacturer’s instructions (New England Biolabs).
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